What changed for Eczema
A plain English summary of what recently moved in the public data Voxsanity tracks for Eczema. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 168 to 167 (-1)
- Trials on record 1,479 to 1,485 (+6)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Eczema in July 2026. Voxsanity tracks 5 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 129 trials tracked for Eczema that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05633355 · results posted 24 July 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05633355) enrolled 187 participants, all of whom received a treatment called rocatinlimab. Of those, 160 people completed the study and 27 did not finish. The trial had one primary outcome measure, which focused on tracking serious unwanted medical events — called treatment-emergent serious adverse events (TESAEs) — meaning significant medical occurrences (such as those requiring hospitalisation, that were life-threatening, or that caused lasting disability) that happened after participants received their first dose. The...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05990725 · results posted 17 July 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 260 people who received the treatment lebrikizumab for eczema (also called atopic dermatitis). Of those, 247 were included in the main analysis group and 243 completed the study. The trial was measuring how well different scoring tools — which rate things like skin redness, thickness, and the area of skin affected — changed over 24 weeks of treatment. There was no comparison (control) group reported in these results, so all figures relate only to the people who received lebrikizumab. The reported data shows that by W...
-
NCT05018806 · results posted 13 July 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05018806) looked at a medicine called rilzabrutinib in people with atopic dermatitis (eczema). A total of 124 people took part across four groups. Participants either received a placebo (a dummy treatment with no active medicine) or rilzabrutinib taken either twice a day (the "BID" group) or three times a day (the "TID" group). The main thing being measured was the change in eczema severity — using a scoring system called the EASI, which rates things like redness, skin thickness, scratching marks, and how much of the body...
-
NCT05651711 · results posted 26 June 2026
According to the results reported on ClinicalTrials.gov, this trial compared two groups of adults with atopic dermatitis (eczema): 183 people received a placebo (an inactive treatment) and 543 people received a medicine called rocatinlimab at a dose of 300 mg given once every four weeks. The trial measured changes in skin inflammation, overall skin appearance, itching, and skin pain at various points over the study period, using standardised scoring tools rated by doctors and participants themselves. The reported data shows that at 16 weeks, 159 out of 543 participants in the rocatinlimab gro...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06238817 · results posted 22 May 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 241 participants across two main groups: 81 people received a vehicle cream (an inactive cream with no active ingredient, used as a comparison) and 160 people received ruxolitinib 1.5% cream (the treatment being studied). The trial was measuring changes in eczema (atopic dermatitis) severity over 8 weeks, using two main scoring tools — one called EASI, which rates the physical signs of eczema on a scale of 0 to 72, and another called IGA, which gives an overall severity rating from 0 (clear) to 4 (severe). The report...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT05590585 · results posted 2 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05590585) enrolled 124 participants, all of whom received at least one dose of dupilumab, a medication being studied for atopic dermatitis (eczema). One hundred and twenty participants completed the study, while four did not. There was no comparison group — everyone in the trial received the same treatment. The trial tracked several measures of eczema severity over time, including a doctor's overall rating of skin condition (called the IGA score) and a detailed scoring system that looks at the area and severity of eczema a...
-
NCT05250115 · results posted 29 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05250115) enrolled 110 people with atopic dermatitis (eczema) who all received a medicine called abrocitinib. Of those 110 participants, 41 completed the study and 69 did not complete it. The trial was measuring how participants' eczema severity changed over time using two main tools: a doctor's overall rating scale (called the IGA, scored 0–4, where lower is better) and a more detailed scoring system that looks at how much of the body is affected and how severe the signs are (called EASI, scored 0–72, where lower is bette...
-
NCT04392154 · results posted 3 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04392154) looked at a medicine called lebrikizumab in people with atopic dermatitis (eczema). During the main part of the trial, which ran for 100 weeks, 141 participants received the medicine once every four weeks (Q4W) and 1,012 participants received it once every two weeks (Q2W). A separate 32-week extension phase then followed for a smaller group of 103 participants, split roughly evenly between a once-every-four-weeks group and a once-every-eight-weeks group. The trial measured several things, including how many peopl...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05507580 · results posted 29 July 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 461 participants with atopic dermatitis (eczema) across two groups during the first phase: 229 received a 15 mg dose of upadacitinib (UPA) and 232 received a 30 mg dose, both without participants knowing which dose they were taking. After this first 12-week phase, participants moved into a second phase where they could be switched to a different dose or stay on the same one, creating four subgroups. The trial used a standard eczema scoring tool called the EASI (scored from 0 to 72, where higher numbers mean more sever...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT05131477 · results posted 3 July 2025
According to the results reported on ClinicalTrials.gov, this trial tested a drug called KY1005 in people with atopic dermatitis (eczema). The trial had two parts. In Part 1, around 390 participants were randomly assigned to receive one of four different doses of KY1005 or a placebo (a dummy treatment with no active ingredient) for 24 weeks. Participants who responded well during Part 1 were then re-randomised into Part 2, where they either continued on KY1005 or were switched to placebo for a further period. The trial used a standard eczema severity scoring tool called the EASI (which runs fr...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05355818 · results posted 2 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05355818) looked at a cream called delgocitinib as a treatment for chronic hand eczema. A total of 98 people took part — 74 were assigned to use the delgocitinib cream and 24 were assigned to use a "vehicle" cream (a cream with no active ingredient, used as a comparison). Of those, 71 and 21 people respectively completed the study. The trial ran for 16 weeks and used several rating tools to measure changes in the appearance and feel of participants' hand eczema. The reported data shows the following numbers at week 16. Fo...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05372653 · results posted 30 March 2025
According to the results reported on ClinicalTrials.gov, this trial looked at two different strengths of a cream called OPA-15406 — a 0.3% strength and a 1% strength — in people with a skin condition (likely eczema, based on the measures used). A total of 41 people started the trial: 12 in the lower-strength group and 29 in the higher-strength group. Of those, 11 and 25 respectively completed the study. The trial measured how participants' skin symptoms changed over four weeks, using two scoring systems — one called the IGA (a researcher's overall rating of skin severity) and one called the EA...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05579899 · results posted 5 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05579899) looked at a skin cream called EVO101 compared to a "vehicle cream" (a cream with no active ingredient, sometimes called a placebo cream) in people with atopic dermatitis, commonly known as eczema. A total of 60 people were assigned to the EVO101 cream group and 59 to the vehicle cream group. The trial ran for 8 weeks and measured things like the area and severity of eczema, how much of the body was affected, and how itchy participants felt. The reported data shows that for the main measure — a scoring system cal...
-
NCT05601882 · results posted 14 February 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 920 adults with atopic dermatitis (eczema) across two treatment groups in the first phase: 462 people received dupilumab and 458 received upadacitinib. The trial was designed in two back-to-back periods running from the start to Week 16, and then from Week 16 to Week 32, with some participants switching or continuing treatment in the second period. The main thing the trial was measuring was how many people, by Week 16, achieved both a 90% or greater reduction in a standard eczema severity score (called EASI, which rat...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04949841 · results posted 20 January 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 801 people with chronic hand eczema (a persistent, inflammatory skin condition affecting the hands) who used a cream called delgocitinib on an as-needed basis — meaning they applied it when they felt they needed it rather than on a fixed schedule. Of those 801 participants, 664 completed the study, while 137 did not. The trial tracked a range of measurements over approximately 36–38 weeks, including the number of side effects that occurred and how participants' hand eczema severity changed over time using two standard...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04195698 · results posted 9 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04195698) enrolled 475 adults in total — 239 in a group that switched from a medicine called dupilumab (300 mg) to upadacitinib (30 mg), and 236 in a group that continued on upadacitinib (30 mg) throughout. The trial was primarily measuring unwanted medical events (called adverse events) that occurred during treatment, as well as changes in laboratory blood test results and physical measurements such as blood pressure, pulse, and weight. The reported data shows that, when it came to general treatment-related adverse event...
-
NCT04872101 · results posted 17 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04872101) enrolled 473 adults with chronic hand eczema — 314 were assigned to use a cream containing delgocitinib (20 mg/g) and 159 were assigned to use a plain cream vehicle (a cream with no active ingredient), which acted as the comparison group. The trial ran for 16 weeks and was primarily measuring how many participants reached a specific level of skin clearance on a five-point severity scale called the IGA-CHE, where a score of 0 means "clear" and 4 means "severe." Reaching the target — called "treatment success" — me...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04773587 · results posted 9 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04773587) enrolled 654 people with atopic dermatitis (eczema) — 433 in the roflumilast cream 0.15% group and 221 in the vehicle cream (a cream without the active ingredient, used as a comparison) group. The trial ran for 4 weeks and was mainly measuring how many participants reached a rating of "clear" or "almost clear" skin on a standard severity scale called the vIGA-AD, which runs from 0 (clear) to 4 (severe). To count as a success on this scale, a participant also needed to improve by at least 2 grades from where they...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05375929 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial studied a medicine called abrocitinib in people with atopic dermatitis (eczema). The main part of the trial enrolled 200 participants, split roughly evenly between a higher dose (200 mg once daily, n=99) and a lower dose (100 mg once daily, n=101), and ran for 12 weeks followed by a 4-week check-in. A smaller sub-study enrolled an additional 35 participants (19 on the higher dose, 16 on the lower dose) who took the medicine for up to one year. The trial was measuring things like unwanted medical events that occurred during the...
-
NCT03985943 · results posted 14 August 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03985943) looked at a medicine called nemolizumab for people with atopic dermatitis (eczema). The trial ran in two stages: an initial 16-week period where 321 people received a placebo (a dummy treatment with no active ingredient) and 620 people received nemolizumab 30 mg, followed by a longer maintenance period running to week 48, where participants were reassigned into four different groups totalling 372 people. The trial was measuring two main things at the 16-week mark: how much the overall skin condition improved (usi...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05194540 · results posted 20 June 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 136 adults who received the medication tralokinumab delivered by an autoinjector (a self-injection pen) for the treatment of eczema (also called atopic dermatitis). Of those who started, 117 completed the trial and 19 did not finish. The trial was measuring how well participants' eczema responded after 16 weeks, using two standard scoring tools: one where a doctor rates overall skin clearance on a scale of 0 (clear) to 4 (severe), and another that measures the area and severity of eczema across the body on a scale of...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02004041 · results posted 11 June 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02004041) enrolled 69 people in total — 34 in the VLY-686 (treatment) group and 35 in the placebo (inactive treatment) group. The trial was measuring changes in itch intensity over approximately 28 days. Participants rated their itch on a 100-millimetre scale, where 0 meant "no itch" and 100 meant "the worst imaginable itch." The trial tracked how much those scores changed from the start of the study to the end. The reported data shows that, on average, people in the VLY-686 group saw their itch score decrease by 40.5 mm...
-
NCT04668066 · results posted 3 June 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04668066) was conducted in two parts and enrolled a total of around 110 participants across many different groups. Part 1 tested a range of single doses and multiple doses of the study drug — given either as a drip into a vein (intravenous) or as an injection under the skin (subcutaneous) — at varying amounts, alongside placebo (dummy treatment) groups. A separate Japanese cohort was also included. Part 2 enrolled 16 participants who received the study drug and 9 who received a placebo, all by intravenous drip. The trial w...
-
NCT05117060 · results posted 31 May 2024
According to the results reported on ClinicalTrials.gov, this trial tested three different doses of an investigational treatment called LEO 152020, plus a placebo (a dummy treatment with no active ingredient), in people with atopic dermatitis (eczema). A total of 216 people started the trial — 61 in the higher dose group, 45 in the middle dose group, 49 in the lower dose group, and 61 in the placebo group. The main thing the trial was measuring was a change in eczema severity using a scoring system called the EASI (Eczema Area and Severity Index), which runs from 0 to 72, where higher numbers...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT04140695 · results posted 14 May 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04140695) enrolled 87 people in total — 43 received a medicine called tradipitant and 44 received a placebo (a dummy treatment with no active ingredient). The trial was measuring itch severity using a tool called the Worst Itch Numeric Rating Scale (WI-NRS), which asks people to rate their itch on a scale from 0 (no itch) to 10 (the worst itch imaginable). The main goal was to see how many participants experienced a meaningful drop in their itch score — specifically, a reduction of at least 4 points from their starting sco...
-
NCT05017480 · results posted 1 May 2024
According to the results reported on ClinicalTrials.gov, this trial looked at a drug called CBP-201 in people with atopic dermatitis (eczema). In the first stage of the trial, 219 people received CBP-201 (given as an injection every two weeks) and 111 people received a placebo (a dummy treatment with no active ingredient). The trial was measuring things like how much the skin's overall appearance improved, how much the affected skin area and severity changed, and how much itching reduced. A second stage then followed, involving a further 311 participants across three groups who continued or sw...
-
NCT04378569 · results posted 5 April 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04378569) tested a cream called ARQ-252 on people with hand eczema. A total of 230 participants were enrolled across two groups, called Cohort 1 and Cohort 2. Cohort 1 was a smaller, earlier group of 7 people who received ARQ-252 cream at a 0.3% strength once daily. Cohort 2 was larger, with the remaining participants split across different versions of the cream — different strengths and how often it was applied (once or twice daily) — as well as a "vehicle cream," which is a plain cream containing no active ingredient, us...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT02589392 · results posted 26 February 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02589392) enrolled 120 people in total — 60 in a group using both a moisturiser and a body wash, and 60 in a group using a body wash only. The trial was measuring how long it took for participants' skin condition to relapse (return or worsen) after a period of treatment. Six people in each group did not complete the study, meaning 54 in each group finished. The reported data shows that the trial tracked "time to relapse," meaning the number of days from the start of the study until a participant's condition came back. Bec...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03667014 · results posted 9 January 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03667014) enrolled 34 adults who received the medication dupilumab for their atopic dermatitis (eczema). Twenty-four participants completed the study, while 10 did not finish. The trial was measuring changes over 16 weeks in a range of self-reported scores covering general wellbeing, skin-related quality of life, itch, pain, sleep quality, and work productivity. The reported data shows the following changes between the start of the trial (baseline) and week 16. For the main measure — the Psychological General Well-Being s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05014438 · results posted 18 October 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT05014438) looked at atopic dermatitis (eczema) and involved a total of 17 people across five groups — one placebo group and four treatment groups, with 3 to 4 people in each group. Of those, 13 completed the study. The trial measured several things related to eczema severity over 16 weeks, including a skin scoring system called the EASI (which rates eczema across the body on a scale of 0 to 72, where lower is better), a doctor's overall rating of skin clearance, itch intensity, and how much of the body's skin surface was a...
See all 129 reported results for Eczema
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a substantial amount of public research money is currently being directed toward eczema, and that investment has been growing year on year. This rising trend is an encouraging sign that the scientific community and research funders see eczema as a priority worth sustained attention. For patients, this generally means that research activity is likely to continue build...
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.